WCN26-3895 EFFICACY OF LONG-ACTING ERYTHROPOIESIS STIMULATING AGENTS (ESAs) IN ANEMIC CHRONIC KIDNEY DISEASE PATIENTS WITH DIABETES MELLITUS: A SUBGROUP ANALYSIS OF A PHASE 3 NON-INFERIORITY TRIAL

Read full text Summarise with VIRAT
Authors: Pringgodigdo Nugroho, Timothy Widjaja
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Erythropoiesis-Stimulating Agents (ESAs) are the cornerstone of therapy for anemia in patients with chronic kidney disease (CKD). Efepoetin alfa, a novel long-acting erythropoietin (EPO)-hybrid Fc fusion protein, was previously shown to be non-inferior to methoxy polyethylene glycol-epoetin beta (mPEG-epoetin beta) for the treatment of anemia in CKD in a pivotal phase 3 trial. The management of anemia in CKD patients with co-existing diabetes mellitus presents a distinct clinical challenge, as this population often exhibits greater difficulty in achieving and maintaining target hemoglobin (Hb) levels compared to non-diabetic counterparts.

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Biosimilars and Bioanalytical Methods Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104614–104614
Publication date
25 March 2026
Language
EN